Results of a study opened at the Assistance Publique-Hôpitaux de Paris evaluating that of Roche (OTCQX: RHHBY -0.6%), Actemra drug arthritis (tocilizumab) in hospital patients with moderate to severe pneumonia with COVID-19 pneumonia has shown therapeutic benefit.
65 patients received tocilizumab + standard treatment (SOC) while 64 patients received SOC. The primary objective was achieved, demonstrating a significantly lower proportion of patients in the tocilizumab arm who died or required ventilation compared to the SOC arm.
The results will be submitted for publication.
Tocilizumab is an interleukin-6 (IL-6) receptor antagonist. IL-6 is a pro-inflammatory protein (cytokine).